Product: ARG1 Antibody
Catalog: DF6657
Source: Rabbit
Application: WB, IHC, IF/ICC, ELISA(peptide)
Reactivity: Human, Mouse, Rat
Prediction: Pig, Xenopus
Mol.Wt.: 35kD; 35kD(Calculated).
Uniprot: P05089
RRID: AB_2838619

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IHC 1:50-1:200, IF/ICC 1:100-1:500, ELISA(peptide) 1:20000-1:40000
*The optimal dilutions should be determined by the end user.
Reactivity:
Human,Mouse,Rat
Prediction:
Pig(82%), Xenopus(83%)
Clonality:
Polyclonal
Specificity:
ARG1 Antibody detects endogenous levels of total ARG1.
RRID:
AB_2838619
Cite Format: Affinity Biosciences Cat# DF6657, RRID:AB_2838619.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

A I; Al; ARG 1; arg1; ARGI1_HUMAN; Arginase 1; Arginase liver; Arginase type I; Arginase, liver; Arginase-1; Arginase1; Liver type arginase; Liver-type arginase; Type I arginase;

Immunogens

Immunogen:

A synthesized peptide derived from human ARG1, corresponding to a region within C-terminal amino acids.

Uniprot:
Gene(ID):
Expression:
P05089 ARGI1_HUMAN:

Within the immune system initially reported to be selectively expressed in granulocytes (polymorphonuclear leukocytes [PMNs]) (PubMed:15546957). Also detected in macrophages mycobacterial granulomas (PubMed:23749634). Expressed in group2 innate lymphoid cells (ILC2s) during lung disease (PubMed:27043409).

Description:
Arginase catalyzes the hydrolysis of arginine to ornithine and urea. At least two isoforms of mammalian arginase exist (types I and II) which differ in their tissue distribution, subcellular localization, immunologic crossreactivity and physiologic function. The type I isoform encoded by this gene, is a cytosolic enzyme and expressed predominantly in the liver as a component of the urea cycle. Inherited deficiency of this enzyme results in argininemia, an autosomal recessive disorder characterized by hyperammonemia. Two transcript variants encoding different isoforms have been found for this gene.
Sequence:
MSAKSRTIGIIGAPFSKGQPRGGVEEGPTVLRKAGLLEKLKEQECDVKDYGDLPFADIPNDSPFQIVKNPRSVGKASEQLAGKVAEVKKNGRISLVLGGDHSLAIGSISGHARVHPDLGVIWVDAHTDINTPLTTTSGNLHGQPVSFLLKELKGKIPDVPGFSWVTPCISAKDIVYIGLRDVDPGEHYILKTLGIKYFSMTEVDRLGIGKVMEETLSYLLGRKKRPIHLSFDVDGLDPSFTPATGTPVVGGLTYREGLYITEEIYKTGLLSGLDIMEVNPSLGKTPEEVTRTVNTAVAITLACFGLAREGNHKPIDYLNPPK

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Xenopus
83
Pig
82
Bovine
73
Sheep
73
Dog
73
Horse
64
Zebrafish
0
Chicken
0
Rabbit
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - P05089 As Substrate

Site PTM Type Enzyme
S16 Phosphorylation
T29 Phosphorylation
K33 Ubiquitination
Y50 Phosphorylation
S62 Phosphorylation
S72 Phosphorylation
S94 Phosphorylation
S102 Phosphorylation
S107 Phosphorylation
S109 Phosphorylation
S163 Phosphorylation
T166 Phosphorylation
C168 S-Nitrosylation
S170 Phosphorylation
K191 Acetylation
S217 Phosphorylation
Y265 Phosphorylation
C303 S-Nitrosylation

Research Backgrounds

Function:

Key element of the urea cycle converting L-arginine to urea and L-ornithine, which is further metabolized into metabolites proline and polyamides that drive collagen synthesis and bioenergetic pathways critical for cell proliferation, respectively; the urea cycle takes place primarily in the liver and, to a lesser extent, in the kidneys.

Functions in L-arginine homeostasis in nonhepatic tissues characterized by the competition between nitric oxide synthase (NOS) and arginase for the available intracellular substrate arginine. Arginine metabolism is a critical regulator of innate and adaptive immune responses. Involved in an antimicrobial effector pathway in polymorphonuclear granulocytes (PMN). Upon PMN cell death is liberated from the phagolysosome and depletes arginine in the microenvironment leading to suppressed T cell and natural killer (NK) cell proliferation and cytokine secretion. In group 2 innate lymphoid cells (ILC2s) promotes acute type 2 inflammation in the lung and is involved in optimal ILC2 proliferation but not survival (By similarity). In humans, the immunological role in the monocytic/macrophage/dendritic cell (DC) lineage is unsure.

Subcellular Location:

Cytoplasm. Cytoplasmic granule.
Note: Localized in azurophil granules of neutrophils (PubMed:15546957).

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Within the immune system initially reported to be selectively expressed in granulocytes (polymorphonuclear leukocytes [PMNs]). Also detected in macrophages mycobacterial granulomas. Expressed in group2 innate lymphoid cells (ILC2s) during lung disease.

Subunit Structure:

Homotrimer. Interacts with CMTM6.

Family&Domains:

Belongs to the arginase family.

Research Fields

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Metabolism > Amino acid metabolism > Arginine biosynthesis.

· Metabolism > Amino acid metabolism > Arginine and proline metabolism.

· Metabolism > Global and overview maps > Metabolic pathways.

· Metabolism > Global and overview maps > Biosynthesis of amino acids.

References

1). Huang R et al. CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling. Cell Death Dis 2020 Apr 16;11(4):234 (PubMed: 32300100) [IF=9.685]

Application: WB    Species: human    Sample: prostate cancer cells

Fig. 3 TAM-secreted CCL5 promoted the invasion of prostate cancer cells and the self-renewal of PCSCs. a, b The reliability of THP1-derived TAMs was validated by analyzing the macrophage surface markers. THP1 monocytes were induced differentiation into macrophages (M0) by 100 ng/ ml PMA treatment for 24 h, which were further transformed into M2 phenotype macrophages (TAMs) by 10 ng/ml IL-4 induction for 72 h. c, d The CM of THP1-derived TAMs significantly promoted EMT, migration and invasion of prostate cancer cells, while CCL5 NA could partly abrogate that. Scale bars represent 200 μm for wound healing assay images and 50 μm for transwell assay images. e The CM of THP1-derived TAMs significantly promoted the self-renewal of PCSCs, while CCL5 NA could partly abrogate that. All values are presented as the mean ± SD. n = 3, *p < 0.05, **p < 0.01.

2). Mai S et al. Oesophageal squamous cell carcinoma–associated IL‐33 rewires macrophage polarization towards M2 via activating ornithine decarboxylase. Cell Prolif 2021 Feb;54(2):e12960. (PubMed: 33305406) [IF=8.755]

Application: IF/ICC    Species: human    Sample: M2 macrophages

FIGURE 2|IL-33 skews M2 macrophage polarization. F, Immunofluorescence staining for IL-33–induced M2 macrophages (scale bar = 20 μm). The green signal represents the staining of activated ornithine decarboxylase, and the blue signal represents the DAPI-stained nuclei. *P < .05; **P < .01; ***P < .001. Bars indicate mean and SEM of triplicate experiments and show a representative experiment of at least 3 independent experiments performed for each panel

Application: WB    Species: human    Sample: M2 macrophages

FIGURE 4|IL-33 promotes M2 macrophage polarization via ornithine decarboxylase (ODC) activation.E, iNOS and ARG1 protein levels were determined by Western blot in IL-33–induced M2 macrophage with or without knocking down ODC. *P < .05; **P < .01; ***P < .001. Bars indicate mean and SEM of triplicate experiments and show a representative experiment of at least 3 independent experiments performed for each panel

3). He P et al. Reduced expression of CENP-E contributes to the development of hepatocellular carcinoma and is associated with adverse clinical features. Biomed Pharmacother 2019 Dec 24;123:109795 (PubMed: 31881483) [IF=7.419]

Application: IHC    Species: mouse    Sample: tumor

Fig. 5.| Down regulation of CENP-E in HCC cells promoted tumor growth of in vivo.(C) Tumor sections were subjected to IHC staining, showing the increased expression of GPC-3 but no difference of ARG-1 expression in CENP-E-low-expressing tumors versus control tumors (ARG-1:P > 0.05, GPC-3:P < 0.05). 40× magnifications, scale bar 100 μm. Statistical significance was tested by Student’s t-test.

4). Lu H et al. Rosiglitazone Suppresses Renal Crystal Deposition by Ameliorating Tubular Injury Resulted from Oxidative Stress and Inflammatory Response via Promoting the Nrf2/HO-1 Pathway and Shifting Macrophage Polarization. Oxid Med Cell Longev 2021 Oct 14;2021:5527137. (PubMed: 34691355) [IF=7.310]

5). Zeng P et al. Protective effects of Da-cheng-qi decoction in rats with intracerebral hemorrhage. Phytomedicine 2021 Sep;90:153630. (PubMed: 34217968) [IF=6.656]

6). Yan S et al. Wu-Mei-Wan Ameliorates Murine Ulcerative Colitis by Regulating Macrophage Polarization. Front Pharmacol 2022 Mar 21;13:859167. (PubMed: 35387334) [IF=5.810]

7). Yu S et al. Fascin-1 Is Highly Expressed Specifically in Microglia After Spinal Cord Injury and Regulates Microglial Migration. Front Pharmacol 2021 Sep 27;12:729524. (PubMed: 34646136) [IF=5.810]

8). Shi X et al. MiR-144-5p limits experimental abdominal aortic aneurysm formation by mitigating M1 macrophage-associated inflammation: Suppression of TLR2 and OLR1. J Mol Cell Cardiol 2020 Apr 9 (PubMed: 32278833) [IF=5.763]

Application: WB    Species: mouse    Sample: RAW264.7 and THP1 cells

Fig. S6.|we analyzed the expression of M2 macrophage markers, IL10 and ARG1,with Western blot analysis in RAW264.7 and THP1 cells, and found that their expression decreased in response to ox-LDL stimulation and partly restored when miR144-5p was overexpressed

9). Zheng Y et al. XIAOPI formula inhibits the pre-metastatic niche formation in breast cancer via suppressing TAMs/CXCL1 signaling. Cell Commun Signal 2020 Mar 26;18(1):48 (PubMed: 32213179) [IF=5.712]

Application: WB    Species: mouse    Sample: RAW264.7 cells

Fig. 1| XIAOPI formula suppresses the polarization of M2 macrophages and CXCL1 expression.a The phenotype changes of RAW264.7 induced by 40 ng/ ml IL-4 and 40 ng/ml IL-13.

10). Gong Q et al. Fractalkine Aggravates LPS-induced Macrophage Activation and Acute Kidney Injury via Wnt/β-catenin Signaling Pathway. J Cell Mol Med 2021 Jul;25(14):6963-6975. (PubMed: 34101346) [IF=5.295]

Application: WB    Species: mouse    Sample: J774A. 1 cells

FIGURE 4|FKN regulated polarization in LPS-induced J774A.1 cells via Wnt/β-catenin signalling. A, B, Western blot analysis and their respective quantitation were performed to detect the expression levels of iNOS, TNF-α, ARG-1 and IL-10 protein in J774A.1 cells.

Application: IF/ICC    Species: mouse    Sample: J774A. 1 cells

FIGURE 4 |FKN regulated polarization in LPS-induced J774A.1 cells via Wnt/β-catenin signalling. E, F, Immunofluorescence analysis was used to ascertained the subcellular localization of iNOS and ARG-1. Scale bars represent 10 μm

Load more

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.